The Deleted in Liver Cancer 1 (Dlc1) tumor suppressor is haploinsufficient for mammary gland development and epithelial cell polarity

BMC Cancer

Volumn 15, Issue 1, 2015, Pages

  Basak, Pratima ^a,b   Dillon, Rachelle ^a   Leslie, Heather ^a   Raouf, Afshin ^a,b   Mowat, Michael R A ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; COLLAGEN; COLLAGENASE; DISPASE; EOSIN; HEMATOXYLIN; MATRIGEL; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SHORT HAIRPIN RNA; DLC-1 (DELETED IN LIVER CANCER) PROTEIN, MOUSE; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; TUMOR SUPPRESSOR PROTEIN;

ALLELE; ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST DEVELOPMENT; BREAST DUCT; BREAST EPITHELIUM CELL; BREAST MALFORMATION; CELL POLARITY; CELL STRUCTURE; CONTROLLED STUDY; DLC1 GENE; FEMALE; GENE EXPRESSION; GENE FUNCTION; GENE LOSS; GENE SILENCING; HAPLOINSUFFICIENCY; HETEROZYGOTE; MAMMARY DUCTAL BRANCHING; MAMMARY DUCTAL THICKENING; MAMMARY GLAND; MASSON TRICHROME STAINING; MORPHOGENESIS; MOUSE; NONHUMAN; PROTEIN CLEAVAGE; PROTEIN FUNCTION; SINGLE CELL ANALYSIS; SOLID ACINAR STRUCTURE; STAINING; STROMA; TERMINAL END BUD DEFORMITY; TUMOR SUPPRESSOR GENE; WILD TYPE; ANIMAL; BREAST TUMOR; CONFOCAL MICROSCOPY; EPITHELIUM CELL; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; GROWTH, DEVELOPMENT AND AGING; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; UDDER; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL POLARITY; EPITHELIAL CELLS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GTPASE-ACTIVATING PROTEINS; HAPLOINSUFFICIENCY; MAMMARY GLANDS, ANIMAL; MICE; MICROSCOPY, CONFOCAL; REAL-TIME POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR PROTEINS;

EID: 84940979094     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-015-1642-x     Document Type: Article

References (52)

1. Ching HC, Naidu R, Seong MK, Har YC, Taib NA. Integrated analysis of copy number and loss of heterozygosity in primary breast carcinomas using high-density SNP array. Int J Oncol. 2011;39:621-33.
2. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;486:346-52.
3. Durkin ME, Yuan BZ, Zhou X, Zimonjic DB, Lowy DR, Thorgeirsson SS, et al. DLC-1:a Rho GTPase-activating protein and tumour suppressor. J Cell Mol Med. 2007;11:1185-207.
4. Yuan BZ, Miller MJ, Keck CL, Zimonjic DB, Thorgeirsson SS, Popescu NC. Cloning, characterization, and chromosomal localization of a gene frequently deleted in human liver cancer (DLC-1) homologous to rat RhoGAP. Cancer Res. 1998;58:2196-9.
5. Xue W, Krasnitz A, Lucito R, Sordella R, VanAelst L, Cordon-Cardo C, et al. DLC1 is a chromosome 8p tumor suppressor whose loss promotes hepatocellular carcinoma. Genes Dev. 2008;22:1439-44.
6. Yuan BZ, Durkin ME, Popescu NC. Promoter hypermethylation of DLC-1, a candidate tumor suppressor gene, in several common human cancers. Cancer Genet Cytogenet. 2003;140:113-7.
7. Xue W, Kitzing T, Roessler S, Zuber J, Krasnitz A, Schultz N, et al. A cluster of cooperating tumor-suppressor gene candidates in chromosomal deletions. PNAS. 2012;109:8212-7.
8. Plaumann M, Seitz S, Frege R, Estevez-Schwarz L, Scherneck S. Analysis of DLC-1 expression in human breast cancer. J Cancer Res Clin Oncol. 2003;129:349-54.
9. Ullmannova V, Popescu NC. Expression profile of the tumor suppressor genes DLC-1 and DLC-2 in solid tumors. Int J Oncol. 2006;29:1127-32.
10. Yuan BZ, Zhou X, Durkin ME, Zimonjic DB, Gumundsdottir K, Eyfjord JE, et al. DLC-1 gene inhibits human breast cancer cell growth and in vivo tumorigenicity. Oncogene. 2003;22:445-50.
11. Goodison S, Yuan J, Sloan D, Kim R, Li C, Popescu NC, et al. The RhoGAP protein DLC-1 functions as a metastasis suppressor in breast cancer cells. Cancer Res. 2005;65:6042-53.
12. Homma Y, Emori Y. A dual functional signal mediator showing RhoGAP and phospholipase C-delta stimulating activities. EMBO J. 1995;14:286-91.
13. Healy KD, Hodgson L, Kim TY, Shutes A, Maddileti S, Juliano RL, et al. DLC-1 suppresses non-small cell lung cancer growth and invasion by RhoGAP-dependent and independent mechanisms. Mol Carcinog. 2008;47:326-37.
14. Wong CM, Lee JM-F, Ching YP, Jin DY, Ng IO. Genetic and epigenetic alterations of DLC-1 gene in hepatocellular carcinoma. Cancer Res. 2003;63:7646-51.
15. Yamaga M, Sekimata M, Fujii M, Kawai K, Kamata H, Hirata H, et al. A PLCdelta1-binding protein, p122/RhoGAP, is localized in caveolin-enriched membrane domains and regulates caveolin internalization. Genes Cells. 2004;9:25-37.
16. Kim TY, Vigil D, Der C, Juliano R. Role of DLC-1, a tumor suppressor protein with RhoGAP activity, in regulation of the cytoskeleton and cell motility. Cancer Metastasis Rev. 2009;28:77-83.
17. Du X, Qian X, Papageorge A, Schetter AJ, Vass WC, Liu X, et al. Functional interaction of tumor suppressor DLC1 and caveolin-1 in cancer cells. Cancer Res. 2012;72:4405-16.
18. Kawai K, Yamaga M, Iwamae Y, Kiyota M, Kamata H, Hirata H, et al. A PLCdelta1-binding protein, p122RhoGAP, is localized in focal adhesions. Biochem Soc Trans. 2004;32:1107-9.
19. Liao YC, Si L, deVere White RW, Lo SH. The phosphotyrosine-independent interaction of DLC-1 and the SH2 domain of cten regulates focal adhesion localization and growth suppression activity of DLC-1. J Cell Biol. 2007;176:43-9.
20. Qian X, Li G, Asmussen HK, Asnaghi L, Vass WC, Braverman R, et al. Oncogenic inhibition by a deleted in liver cancer gene requires cooperation between tensin binding and Rho-specific GTPase-activating protein activities. PNAS. 2007;104:9012-7.
21. Yam JWP, Ko FCF, Chan CY, Jin DY, Ng IO. Interaction of deleted in liver cancer 1 with Tensin2 in Caveolae and implications in tumor suppression. Cancer Res. 2006;66:8367-72.
22. Li G, Du X, Vass WC, Papageorge AG, Lowy DR, Qian X. Full activity of the deleted in liver cancer 1 (DLC1) tumor suppressor depends on an LD-like motif that binds talin and focal adhesion kinase (FAK). PNAS. 2011;108:129-34.
23. Silberstein GB. Postnatal mammary gland morphogenesis. Microsc Res Tech. 2001;52:155-62.
24. Hinck L, Silberstein G. Key stages in mammary gland development: the mammary end bud as a motile organ. Breast Cancer Res. 2005;7:245-51.
25. Roignot J, Peng X, Mostov K. Polarity in Mammalian epithelial morphogenesis. Cold Spring Harb Perspect Biol. 2013;5. doi: 10.1101/cshperspect.a013789 .
26. Nelson CM, Bissell MJ. Modeling dynamic reciprocity: engineering three-dimensional culture models of breast architecture, function, and neoplastic transformation. Semin Cancer Biol. 2005;15:342-52.
27. Wodarz A, Nathke I. Cell polarity in development and cancer. Nat Cell Biol. 2007;9:1016-24.
28. McCormack J, Welsh NJ, Braga VMM. Cycling around cell-cell adhesion with Rho GTPase regulators. J Cell Sci. 2013;126:379-91.
29. Chakravarty G, Hadsell D, Buitrago W, Settleman J, Rosen JM. p190-B RhoGAP regulates mammary ductal morphogenesis. Mol Endocrinol. 2003;17:1054-65.
30. Heckman-Stoddard BM, Vargo-Gogola T, Herrick MP, Visbal AP, Lewis MT, Settleman J, et al. P190A RhoGAP is required for mammary gland development. Dev Biol. 2011;360:1-10.
31. Duan L, Chen G, Virmani S, Ying G, Raja SM, Chung BM, et al. Distinct roles for Rho versus Rac/Cdc42 GTPases downstream of Vav2 in regulating mammary epithelial acinar architecture. J Biol Chem. 2010;285:1555-68.
32. Sabbir M, Wigle N, Loewen S, Gu Y, Buse C, Hicks G, et al. Identification and characterization of Dlc1 isoforms in the mouse and study of the biological function of a single gene trapped isoform. BMC Biol. 2010;8:17.
33. Chatterjee S, Bacopulos S, Yang W, Amemiya Y, Spyropoulos D, Raouf A, et al. Loss of Igfbp7 causes precocious involution in lactating mouse mammary gland. PLoS ONE. 2014;9:e87858.
34. Debnath J, Muthuswamy SK, Brugge JS. Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods. 2003;30:256-68.
35. Raouf A, Zhao Y, To K, Stingl J, Delaney A, Barbara M, et al. Transcriptome analysis of the normal human mammary cell commitment and differentiation process. Cell Stem Cell. 2008;3(1):109-18.
36. Stewart SA, Dykxhoorn DM, Palliser D, Mizuno H, Yu EY, An DS, et al. Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA. 2003;9:493-501.
37. Chu JH, Yu S, Hayward SW, Chan FL. Development of a three-dimensional culture model of prostatic epithelial cells and its use for the study of epithelial-mesenchymal transition and inhibition of PI3K pathway in prostate cancer. Prostate. 2009;69:428-42.
38. Zhang Y, Yan W, Jung YS, Chen X. PUMA cooperates with p21 to regulate mammary epithelial morphogenesis and Epithelial-To-Mesenchymal transition. PLoS ONE. 2013;8:e66464.
39. Ren XD, Schwartz MA. Determination of GTP loading on Rho. In: Balch WE, editor. Methods in enzymology part D: regulators and effectors of small GTPases. Volume 325 editionAmsterdam: AcademicPress; 2000. p. 264-72.
40. Gauger K, Shimono A, Crisi G, Schneider S. Loss of sfrp1 promotes ductal branching in the murine mammary gland. BMC Dev Biol. 2012;12:25.
41. Su L, Pertz O, Mikawa M, Hahn K, Parsons SJ. p190RhoGAP negatively regulates Rho activity at the cleavage furrow of mitotic cells. Exp Cell Res. 2009;315:1347-59.
42. Holeiter G, Heering J, Erlmann P, Schmid S, Jahne R, Olayioye MA. Deleted in liver cancer 1 controls cell migration through a Dia1-dependent signaling pathway. Cancer Res. 2008;68:8743-51.
43. Kawai K, Iwamae Y, Yamaga M, Kiyota M, Ishii H, Hirata H, et al. Focal adhesion-localization of START-GAP1/DLC1 is essential for cell motility and morphology. Genes Cells. 2009;14:227-41.
44. Wong CC-L, Wong CM, Ko FC-F, Chan LK, Ching YP, Yam JW-P, et al. Deleted in Liver Cancer 1 (DLC1) negatively regulates Rho/ROCK/MLC pathway in hepatocellular carcinoma. PLoS ONE. 2008;3:e2779.
45. Zuo Y, Berdeaux R, Frost JA. The RhoGEF Net1 is required for normal mammary gland development. Mol Endocrinol. 2014;28:1948-60.
46. Naylor MJ, Ormandy CJ. Mouse strain-specific patterns of mammary epithelial ductal side branching are elicited by stromal factors. Dev Dyn. 2002;225:100-5.
47. Samuel MS, Lopez JI, McGhee EJ, Croft DR, Strachan D, Timpson P, et al. Actomyosin-mediated cellular tension drives increased tissue stiffness and b-catenin activation to induce interfollicular epidermal hyperplasia and tumor growth. Cancer Cell. 2011;19:776-91.
48. Jechlinger M, Podsypanina K, Varmus H. Regulation of transgenes in three-dimensional cultures of primary mouse mammary cells demonstrates oncogene dependence and identifies cells that survive deinduction. Genes Dev. 2009;23:1677-88.
49. Bissell MJ, Hines WC. Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat Med. 2011;17:320-9.
50. Klein G. Toward a genetics of cancer resistance. PNAS. 2009;106:859-63.
51. Haverty PM, Fridlyand J, Li L, Getz G, Beroukhim R, Lohr S, et al. High-resolution genomic and expression analyses of copy number alterations in breast tumors. Genes Chromosom Cancer. 2008;47:530-42.
52. Hawthorn L, Luce J, Stein L, Rothschild J. Integration of transcript expression, copy number and LOH analysis of infiltrating ductal carcinoma of the breast. BMC Cancer. 2010;10:460.